Expert Review of Pharmacoeconomics & Outcomes Research

Papers
(The H4-Index of Expert Review of Pharmacoeconomics & Outcomes Research is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
A landscape analysis and discussion of value of gene therapies for sickle cell disease27
Content and cost of waste pharmaceuticals collected by pharmacies for disposal20
How do patients value features of biological medicine in rheumatoid arthritis? A discrete choice experiment20
Adherence to augmentation therapy for the treatment of major depressive disorder20
A cost-effectiveness analysis of RefluxStop against relevant therapeutic alternatives for chronic gastroesophageal reflux disease in Sweden15
Healthcare costs, resource utilization, and productivity loss associated with colorectal cancer screening14
Economic evaluation of interventions to improve medication adherence among patients with chronic diseases: an overview of systematic reviews13
Analysis of prescriptive monitoring regarding the current therapeutic landscape of rheumatoid arthritis: the experience of an Italian local health authority13
The cost-of-illness of multiple sclerosis in Jordan13
Burden of ischemic heart disease in Spain: incidence, hospital mortality and costs of hospital care13
The hidden burden of atopic dermatitis in central and Eastern European countries13
The implications of cardiac device cybersecurity responsibilities and challenges faced by policymakers, manufacturers, and patients12
0.062836885452271